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We have determined previously that IGF-I is dependent on
the presence of IGF binding protein-1 (IGFBP-1) to act as a
wound healing agent. We sought to determine the mecha-
nism whereby IGFBP-1 is able to enhance IGF-I bioactivity.
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) the ability of IGFBP-1 to interact with an in-




) the binding of IGF-I by IGFBP-1.
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1 integrin to selectively abrogate each of these interac-
tions. We also tested the ability of IGFBP-2, a related bind-
ing protein which has an arginine-glycine-aspartate se-
quence but does not associate with integrin family members,
to enhance IGF-I bioactivity. Full-thickness dermal wounds
were created on rabbit ears; various combinations of native
IGF-I, native IGFBP-1, native IGFBP-2, and their respective
analogues/mutants were applied to each wound. Wounds
were harvested 7 d later for analysis. Only native IGF-I in
combination with native IGFBP-1 was effective as a wound
healing agent, enhancing reepithelialization and granula-

















 0.008 and 0.016, respectively). The same doses of
IGF-I/WGD-IGFBP-1, des(1-3)IGF-I/IGFBP-1, and IGF-I/
IGFBP-2 were ineffective. We propose that IGF-I physi-
cally interacts with IGFBP-1 and that IGFBP-1 also binds









interaction is unique to IGFBP-1 as the closely related IG-
FBP-2 had no effect, a finding consistent with its inability to
bind to integrin receptors. Our results suggest that activa-








1 integrin is re-


























Wound repair is a complex biological phenomenon. The nor-
mal repair process is dependent upon protein synthesis, matrix
deposition, cellular migration, and replication (1, 2). These di-
verse processes are orchestrated by environmental signals such
as extracellular matrix molecules and peptide growth factors.
While an interaction between these different components has
been assumed, only recently have specific relationships linking
growth factors and the extracellular environment begun to be
elucidated (3–8).
Insulin-like growth factor-I (IGF-I) is a peptide present in
wounds and is hypothesized to play a major role in tissue re-
pair (9–12) since it can stimulate extracellular matrix deposi-
tion and fibroblast growth in vitro. IGF-I’s actions are modu-
lated by proteins found in the pericellular space that have been




 The six members
of the IGFBP family have become increasingly appreciated as
powerful determinants of IGF-I bioactivity (13–15). However,
much remains to be learned about the exact mechanisms
whereby they modulate IGF-I actions.
IGFBP-1 and IGFBP-2 are two of these binding proteins;
they are unique among members of the IGFBP family in hav-
ing an arg-gly-asp (RGD) sequence. IGFBP-1 has been dem-
onstrated to have both inhibitory as well as potentiating effects
on IGF-I actions in vitro (15). Interestingly, it has been shown








1 integrin receptor (16). IG-
FBP-2, although less thoroughly researched than IGFBP-1, is
also known to both enhance as well as diminish the effects of
IGF-I (17–19); an important characteristic distinguishing it
from IGFBP-1 is that IGFBP-2 is not known to bind to inte-
grin receptors despite the fact that it contains an RGD motif
(16). The effects of IGFBP-2 on wound healing have not been
studied.
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 CHO, Chinese hamster ovary;
des(1-3)IGF-I, destripeptide IGF-I; GAG, glycosaminoglycan; IG-












Integrins are classically considered the archetypal matrix
adhesion receptors. However, the past few years have brought
about a greater appreciation of the functional repertoire of the
integrins, and they are now known to be involved not only in
adhesion, but also in such processes as morphogenesis, cell mi-
gration, and signal transduction (7, 20). In particular, their
roles in wound repair are areas of active investigation, and cur-
rently it is known that expression of the integrin subtypes is a
dynamically regulated process throughout the various stages of
dermal repair (21–24). Growth factors have been shown to in-
fluence expression of integrin family members in tissue repair
(25–27). However, a direct interaction between growth factor
receptor family members and integrin receptors has not been
demonstrated in in vivo wound healing assays.
Our lab has previously shown that IGF-I is as effective a




1 and PDGF-BB in our wound heal-
ing models, but it requires the presence of IGFBP-1 to have an
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g per wound in
the presence of IGFBP-1 enhanced wound healing 80–100%
over control wounds. We have attempted to determine a
mechanistic explanation for these prior observations. We used
a naturally occurring IGF-I analogue [destripeptide IGF-I, or
des(1-3)IGF-I] to disrupt binding protein/IGF-I interactions.
This analogue binds to the IGF-I receptor with normal affinity
yet associates very poorly with IGFBP-1 (17, 30–32), allowing
us to determine whether an actual physical association be-
tween IGF-I and IGFBP-1 was necessary. We also tested the
importance of the IGFBP-1/integrin interaction by using a syn-
thetic mutant form of IGFBP-1 which has its RGD binding site
converted to WGD. This amino acid substitution renders it un-








1 integrin in vitro while maintain-
ing its normal affinity for IGF-I (16). Further analysis of the
requirement for integrin binding was obtained by testing the
ability of IGFBP-2 to enhance IGF-I’s vulnerary activity. Our
results suggest a novel role for IGFBP-1, as a conduit modulat-







Recombinant human IGF-I, des(1-3)IGF-1, and IGFBP-1





 95% homogeneity. They were generously supplied by Dr.
George N. Cox (Synergen Corp., Boulder, CO). WGD-IGFBP-1 was
prepared and purified as described previously (16). Briefly, a full-
length human IGFBP-1 cDNA served as a template for PCR site-










fied mutant IGFBP-1 cDNA was then purified and ligated into a
pNUT expression vector. This vector was then transfected into Chi-
nese hamster ovary (CHO) cells, which were then selected and ampli-
fied into a stable cell line with methotrexate. The mutant IGFBP-1
that was secreted into the medium was then purified and concen-
trated for use in the rabbit ear dermal ulcer experiments. This mutant
has been shown to have an affinity for IGF-I that is similar to native








1 integrin that is present on CHO
cell surfaces (16). To ensure that equal amounts of protein were
added to each wound the protein content of the purified WGD-
IGFBP-1 samples was quantitated by amino acid composition analy-
sis. Bovine IGFBP-2 was generously provided by Dr. Ted Busby




All experiments were performed with the ap-
proval of the Northwestern University Institutional Review Board.
An established rabbit ear full-thickness dermal ulcer model was used
as a wound healing assay (33). Since the wound is noncontractile it al-
lows for accurate and reproducible histologic measurements of new
granulation tissue and reepithelialization. On day 0, New Zealand
White rabbits (2.5–3.5 kg) were anesthetized with ketamine and xyla-
zine and, using a 6-mm biopsy punch, four circular full-thickness
wounds that extended to the level of bare cartilage were created on
the ventral surface of each ear. Different combinations of IGF-I,
des(1-3)IGF-1, and the binding proteins were applied locally at the
time of wounding (see below). Rabbits were then returned to their
cages and provided food and water ad libitum. All wounds were har-
vested on postwounding day 7. Any wounds that showed signs of in-








Treatment groups were divided into the fol-






































) IGF-I with native IGFBP-1 at a combination
















































































 8). These doses of IGFBP-1 and IGF-I were chosen as
they have been shown to cause an optimal increase in wound healing
in previous experiments (28, 29). The dose of IGFBP-2 was selected
to maintain a molar ratio of IGF-I to IGFBP-2 that was equal to the
molar ratio of IGF-I to IGFBP-1. All proteins were concentrated and






















 (AN-Con Genetics Inc., Melville, NY) for routine he-





measurements were taken for determination of new granulation tis-
sue area as well as area covered by new epithelium. The wounds of
some groups were also stained with Sirius red F3BA staining for fi-




m sections) and Alcian blue





m sections). All samples were analyzed under a
magnification of 100. The Sirius red–stained slides were evaluated
with plane-polarized light. Mature collagen bundles showed as yellow
fibrils, whereas newly formed collagen and fibronectin stained green
or red. The amount of newly formed collagen in the granulation tis-
sue was then estimated as a percentage of the total granulation tissue
as described previously (29, 34, 35). The percentage of GAG staining
was likewise estimated using Alcian blue–stained slides (29). All de-
terminations were done comparing treated wounds with control
wounds treated with vehicle alone and are depicted as percent change
over control wounds.










 test for each reagent and different combinations
studied using Excel version 5.0 (Microsoft Corporation). All compar-












Fig. 1 shows epithelialization on day 7 after wounding among
all the groups. Neither IGF-I nor IGFBP-1 by itself was effec-
tive in enhancing epithelialization as compared with wounds
treated with vehicle alone. This result confirms our previous
studies (28, 29). IGFBP-2 by itself was also ineffective. Like-
wise, there were no statistical differences between wounds
treated with vehicle and wounds treated with the IGF-I/WGD-















wounds treated with native IGF-I combined with native IG-
FBP-1 showed enhanced epithelialization, demonstrating a
64% increase in new epithelium over control wounds treated

















A similar trend was noted in granulation tissue deposition

















in granulation tissue volume is seen in wounds treated with the
native IGF-I/native IGFBP-1 mixture. In contrast there is no
increase in wounds treated with the other combinations when
compared with control wounds treated with vehicle alone.
Fig. 3 is a photomicrograph comparing control wounds
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Note the dramatic increase in granulation tissue area and reep-
ithelialization in the IGF-I/IGFBP-1–treated sample, with the
entire frame showing the large amount of newly deposited, im-
mature granulation tissue. Also note the large increase in the
number of suprabasal keratinocytes, which is reflected in the
increased height of the epidermis. Not shown are the wounds
treated with IGF-I and IGFBP-2; healing in these wounds is
minimal and indistinguishable from paired wounds treated
with vehicle alone. By contrast, the other three groups show
small amounts of healing. The mature collagen bundles of un-
wounded dermis can be seen on the left in each frame. Alcian
blue staining of these wounds shows an increase in the amount
of GAG, while Sirius red staining reveals significant new col-
lagen deposition within the granulation tissue area and newly
formed basement membrane zone. These increases are sum-
marized in Table I.
Fig. 4 compares the magnitude of the effects of the IGF-I/
IGFBP-1 mixture on granulation tissue deposition with the
previously published effects of other growth factors that have
been tested by this lab in the rabbit ear dermal ulcer model. As
is apparent, the effects of the IGF-I/IGFBP-1 mixture are sub-
stantial and compare favorably with the vulnerary abilities of




1, basic fibroblast growth
factor, and PDGF-BB (33, 34).
Figure 1. Only IGF-I in combination with 
IGFBP-1 is able to enhance epithelializa-
tion in an open wound model. The values 
depicted represent percent increase in epi-
thelialization of wounds treated with the 
different regimens, as measured histomor-
phometrically, over wounds treated with 
vehicle alone. The error bars represent the 
standard error of the mean.
Figure 2. Only IGF-I in combination with 
IGFBP-1 is able to enhance granulation 
tissue deposition. The values depicted rep-
resent percent increase in granulation tis-
sue volume in treated wounds over control 
wounds treated with vehicle alone.
 






We report in this paper an explanation for the previously de-
scribed enhancement by IGFBP-1 of IGF-I bioactivity in our
animal wound models (28, 29). The enhancement of IGF-I ac-
tions by binding proteins has been reported for several in vitro
test systems (13, 36–40). Although many explanations have
been proposed, there does not appear to be one common
mechanism by which the binding proteins potentiate IGF-I ac-
tivity. This variability may be a consequence of the heteroge-
neity in the structure of the six IGFBPs, the various cell types
studied, and the experimental conditions used (for review see
reference 13). For example, IGFBP-3 has been reported most
commonly to inhibit IGF-I. However, pretreatment of cul-
tured cells with IGFBP-3 enhances IGF-I actions when IGF-I
is added later (37, 41). This change correlates strongly with
proteolytic cleavage of IGFBP-3, which results in a decrease in
the affinity of IGFBP-3 for IGF-I (42). It also correlates with
the capacity of this binding protein to adhere to cell surfaces
(40, 43), perhaps to an as yet uncharacterized IGFBP-3 recep-
tor. In a more complicated system such as an experimental
wound, IGFBP-3 has likewise been reported to enhance repair
(44, 45), albeit in a “dead space” wound chamber model using
a multiple dosing regimen. In our models, IGFBP-3 does not
enhance IGF-I bioactivity (Galiano, R.D., J.D. Davidson, and
T.A. Mustoe manuscript in preparation). Since IGFBP-3 does
not contain an RGD sequence, it has been presumed to poten-
tiate IGF-I’s activity by protecting it from the proteases found
Figure 3. Photomicrograph (3200) of hematoxylin and eosin–stained slide of (A) an untreated wound at day 7 after wounding and (B) a day 7 
wound treated with 5 mg of IGF-I in combination with 1.5 mg of IGFBP-1. Note the dramatic increase in the amount of new granulation tissue as 
well as the increase in new epithelium. Using equivalent doses of (C) des(1-3)IGF-I/IGFBP-1 and (D) IGF-I/WGD-IGFBP-1 did not produce a 
demonstrable effect on wound healing when compared with control wounds.
 
Table I. Effects on Extracellular Matrix Components in 
Granulation Tissue
 


































































GAG and collagen deposition elicited by the regimens listed are com-
pared with control wounds treated with vehicle alone and are presented
as percentage over control6SEM. *P , 0.05.
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at the wound site or from clearance or by making it more ac-
cessible to cell membrane–associated IGF-I receptors.
IGFBP-1 has also been reported to have inhibiting or po-
tentiating activities (36, 39, 46, 47). In some instances, this ap-
pears to be attributable to a reduced affinity of dephosphory-
lated IGFBP-1 for IGF-I, which more nearly approximates the
affinity of the type I IGF-I receptor (46). Our earliest report
showed that the phosphorylated form of IGF-I inhibits IGF-I’s
vulnerary effects, whereas the unphosphorylated form potenti-
ates it (28). This variable response to IGFBP-1 has also been
confirmed in cell culture experiments (47). Much of the earlier
confusion in the literature regarding the bimodal effects of IG-
FBP-1 can be explained on the basis that these early experi-
ments often used crudely purified IGFBP-1 which had varying
amounts of the phosphorylated and unphosphorylated forms.
However, all the mechanisms proposed to date have suggested
that IGFBP-1 has a passive role in modulating IGF-I actions,
one that is dictated by its relative affinity for IGF-I as com-
pared with other binding proteins or with the IGF-I receptor.
IGFBP-1 is unique from other binding proteins in several
ways. It differs from most of the other IGFBPs in its tissue ex-
pression patterns, its sensitivity to regulation by insulin, the
regulation of its affinity for IGF-I via changes in its phosphory-
lation state, and most interestingly in containing an RGD se-
quence. IGFBP-1 stimulates cell migration directly in vitro by
binding to the a5b1 integrin receptor (16). This effect does not
appear to be mediated through other integrin receptors. As
noted in prior reports, when CHO or aortic smooth muscle cell
surface proteins were radiolabeled and equilibrated with an
IGFBP-1 affinity column, only the a5b1 integrin heterodimer
bound to the column. Several radiolabeled integrins, including
a1, a2, a3, a5, b1, b3, and b5 could be immunoprecipitated
from the cell lysates (16, 48), but no other integrins bound to
IGFBP-1. Therefore, we believe that the effects we are seeing
in our model are most likely due to the binding of IGFBP-1 to
the a5b1 integrin. However, we cannot definitively rule out
other mechanisms by which IGF-I and IGFBP-1 might func-
tion to enhance wound healing. Although we did not see any
effects on wound healing when we used IGFBP-1 by itself, we
are not surprised since wound healing is a complex biological
phenomenon of which cell migration is but one component. A
growth factor or vulnerary agent must do more than simply in-
crease cell motility to have a demonstrable effect on wound
healing parameters. However, in this study we show that the
ability of IGFBP-1 to bind to an integrin family member (most
likely the a5b1 integrin) appears to be necessary in order for
IGF-I to enhance wound repair since the WGD-IGFBP-1 mu-
tant (which will not bind to the a5b1 integrin [16]) had no ef-
fect. Moreover, IGFBP-1 must be physically complexed to
IGF-I, since the des(1-3)IGF-I analogue is also ineffective. Al-
though we have not proven definitively that a quaternary in-
teraction is required, these observations suggest strongly that
the IGF-I/IGFBP-1 mixture enhances healing by an activation
of both integrin and growth factor–mediated signaling path-
ways.
IGFBP-2, while containing an RGD motif, is not known to
bind to integrin receptors that are expressed on the surfaces of
CHO or aortic smooth muscle cells (49). This is not surprising
or unexpected since the presence of an RGD sequence is in
many cases neither necessary nor sufficient for the binding of
other matrix molecules to integrin receptors. Our demonstra-
tion that IGF-I, at an optimal wound healing dose, is ineffec-
tive when combined with IGFBP-2 is further evidence that the
binding of IGFBP-1 to an integrin receptor is the crucial link
underlying its ability to enhance IGF-I bioactivity in this
model.
The integrin family of receptors, although classically con-
sidered passive adhesion molecules, is known to mediate many
varied effects through signal transduction pathways, many of
which are shared with growth factors and cytokines. For exam-
ple, integrin activation has been shown to phosphorylate not
only integrin-associated focal adhesion kinase, but also down-
stream molecules such as IRS-1 (50), Grb2 (51), and the MAP
kinases (52, 53), all of which are also part of the IGF-I–trig-
gered signaling cascade (for reviews see references 15 and 54).
Since IGF-I is considered a weak mitogen by itself, a simulta-
neous activation of both the IGF-I and integrin signal trans-
duction pathways may be the mechanism accounting for the
synergistic effects seen in our wound models. This conclusion
is strengthened by the recent observation of Vuori and Ruos-
Figure 4. The effects of IGF-I/IGFBP-1 on 
granulation tissue deposition are com-
pared with those of other growth factors 
tested in the rabbit ear dermal ulcer model.
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lahti (50) showing that activating the avb3 integrin receptor
signals a pancreatic cell line to respond to insulin stimulation
with increased DNA synthesis. In accordance with this hypoth-
esis, recent evidence in vitro also highlights the importance of
interactions between integrin and classical growth factor sig-
naling pathways, with several groups reporting evidence show-
ing integration of integrin and growth factor receptor signal
transduction pathways (55–57). Since a physical association
between IGF-I and IGFBP-1 also appears to be essential for
IGFBP-1 to have potentiating effects on IGF-I activity in our
model, IGFBP-1 could serve to bring the IGF-I receptor and
the integrin receptor into close proximity, and perhaps thereby
bring their intracellular effector molecules into close proxim-
ity. While it now appears clear that integrins and growth fac-
tors interact at the molecular level, our report is the first to
demonstrate not only that there is an effector molecule that
brings about this association (i.e., IGFBP-1) but also this is the
first study suggesting a role for a growth factor–integrin inter-
action in an in vivo biological process, in this case wound heal-
ing. Since tissue repair consists of a multitude of interactions
between molecules involved in migration, in proliferation, and
in matrix synthesis, it would not be surprising if further inter-
actions between these processes at the cellular level were elu-
cidated. This would be of importance in unraveling the cellular
and molecular events that determine how wound repair en-
sues.
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